Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 621.9% in January

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 2,541 shares, a growth of 621.9% from the December 31st total of 352 shares. Based on an average daily trading volume, of 25,320 shares, the short-interest ratio is presently 0.1 days. Approximately 0.2% of the company’s shares are short sold. Approximately 0.2% of the company’s shares are short sold. Based on an average daily trading volume, of 25,320 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

A number of brokerages recently issued reports on BOLT. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. HC Wainwright set a $7.00 target price on Bolt Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, October 20th. Finally, Zacks Research lowered shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $34.00.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of large investors have recently bought and sold shares of the business. Squarepoint Ops LLC boosted its position in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after acquiring an additional 2,448 shares in the last quarter. Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics in the 3rd quarter worth $85,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth $89,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Up 8.2%

Shares of BOLT traded up $0.54 during midday trading on Tuesday, reaching $7.09. 19,408 shares of the stock were exchanged, compared to its average volume of 19,446. The company has a market capitalization of $13.61 million, a P/E ratio of -0.32 and a beta of 0.91. The company has a current ratio of 3.57, a quick ratio of 3.57 and a debt-to-equity ratio of 0.65. Bolt Biotherapeutics has a 52 week low of $4.41 and a 52 week high of $10.50. The company’s 50 day moving average is $5.60 and its two-hundred day moving average is $5.51.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($3.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $0.82 million. On average, sell-side analysts anticipate that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.